When the FDA takes action against developers of diagnostic tests, it seems to come primarily during times when new tests are desperately needed. Will Rinehart of the Center for Growth and Opportunity discusses the problem.
Allowing medical services to cross state lines more easily may prove crucial during this stressful time for our medical system. Many states and the feds are wisely getting out of the way. Jeff Singer comments.